New Analyses Allow Restart Of Ipsen's Palovarotene Clinical Program
FDA's Partial Clinical Hold For Patients Under 14 Remains
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.
